Research programme: antibacterials - Hsiri Therapeutics

Drug Profile

Research programme: antibacterials - Hsiri Therapeutics

Alternative Names: HT-06; HT-07; HT-10

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator University of Notre Dame
  • Developer Hsiri Therapeutics
  • Class Antibacterials
  • Mechanism of Action Bacterial growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 16 Jun 2016 Preclinical trials in Bacterial infections in USA (unspecified route)
  • 16 Jun 2016 Pharmacodynamics data from an in vitro study in bacterial infections released by Hsiri Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top